Desipramine: Difference between revisions
(Blanked the page) |
No edit summary |
||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | |||
|authorTag={{PB}} | |||
|genericName=Desipramine | |||
|aOrAn=a | |||
|drugClass=Tricyclic antidepressant | |||
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | |||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |||
|fdaLIADAdult=<b>Condition 1</b> | |||
* Dosing Information | |||
:: (Dosage) | |||
|offLabelAdultGuideSupport=<b>Condition 1</b> | |||
* Developed by: (Organization) | |||
* Class of Recommendation: (Class) (Link) | |||
* Strength of Evidence: (Category A/B/C) (Link) | |||
* Dosing Information/Recommendation | |||
:* (Dosage) | |||
|offLabelAdultNoGuideSupport=<b>Condition 1</b> | |||
* Dosing Information | |||
:* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Desipramine in adult patients. | |||
|fdaLIADPed=<b>Condition 1</b> | |||
* Dosing Information | |||
:: (Dosage) | |||
|offLabelPedGuideSupport=<b>Condition 1</b> | |||
* Developed by: (Organization) | |||
* Class of Recommendation: (Class) (Link) | |||
* Strength of Evidence: (Category A/B/C) (Link) | |||
* Dosing Information/Recommendation | |||
:* (Dosage) | |||
|offLabelPedNoGuideSupport=<b>Condition 1</b> | |||
* Dosing Information | |||
:* There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Desipramine in pediatric patients. | |||
|contraindications=* Condition 1 | |||
* Condition 2 | |||
* Condition 3 | |||
* Condition 4 | |||
* Condition 5 | |||
|warnings=<b>Conidition 1</b> | |||
(Description) | |||
|clinicalTrials=<b>Central Nervous System</b> | |||
: (list/description of adverse reactions) | |||
<b>Cardiovascular</b> | |||
: (list/description of adverse reactions) | |||
<b>Respiratory</b> | |||
: (list/description of adverse reactions) | |||
<b>Gastrointestinal</b> | |||
: (list/description of adverse reactions) | |||
<b>Hypersensitive Reactions</b> | |||
: (list/description of adverse reactions) | |||
<b>Miscellaneous</b> | |||
: (list/description of adverse reactions) | |||
|postmarketing=<b>Central Nervous System</b> | |||
: (list/description of adverse reactions) | |||
<b>Cardiovascular</b> | |||
: (list/description of adverse reactions) | |||
<b>Respiratory</b> | |||
: (list/description of adverse reactions) | |||
<b>Gastrointestinal</b> | |||
: (list/description of adverse reactions) | |||
<b>Hypersensitive Reactions</b> | |||
: (list/description of adverse reactions) | |||
<b>Miscellaneous</b> | |||
: (list/description of adverse reactions) | |||
|drugInteractions=* (Drug 1) | |||
:* (Description) | |||
* (Drug 2) | |||
:* (Description) | |||
* (Drug 3) | |||
:* (Description) | |||
|alcohol=Alcohol-Desipramine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |||
}} | |||
|fileName=}} | |||
{{Drugbox| | |||
|IUPAC_name = 10, 11-dihydro-5-[3-(methylamino) propyl]-5H-dibenz[b,f]azepine monohydrochloride | |||
| image = Desipramine.svg | |||
| width=150 | |||
| CAS_number=50-47-5 | |||
| ATC_prefix=N06 | |||
| ATC_suffix=AA01 | |||
| ATC_supplemental= | |||
| PubChem=2995 | |||
| DrugBank=APRD00022 | |||
| C=18 | H=22 | N=2 | |||
| molecular_weight = 266.381 | |||
| bioavailability= 73-92% | |||
| metabolism = [[Hepatic]] | |||
| elimination_half-life= 21-23 hours | |||
| excretion = [[Renal]] | |||
| pregnancy_category = | |||
| legal_status = Rx only | |||
| routes_of_administration= oral | |||
}} | |||
'''Desipramine''' is a [[tricyclic antidepressant]] (TCA) that inhibits the reuptake of [[norepinephrine]]. It is sold under the brand names '''Norpramin'''® and '''Pertofrane'''®. It is used to treat [[clinical depression|depression]], but not considered a first line treatment since the introduction of [[SSRI]] [[antidepressants]]. Desipramine is an active [[metabolite]] of [[imipramine]]. | |||
Along with other tricyclics, desipramine has found use in treating [[neuropathic pain]]. The mechanism of | |||
action seems to involve the activation, through norepinephrine reuptake inhibition, of descending pathways in the [[spinal cord]] that block pain signals from ascending to the [[brain]]. Desipramine is one of the most potent and selective | |||
medications in this respect. It may also be used to treat symptoms of [[Attention Deficit Disorder]], as the underproduction of norepinephrine has been increasingly linked to symptoms associated with Attention Deficit Disorder. | |||
== Genotoxity == | |||
Desipramin has been shown to be [[genotoxic]] in fruit flies and associated with an increased risk of breast cancer in women.<ref>British Journal of Cancer 2002: volume 86, pages 92-97</ref> | |||
==See also== | |||
* [[antidepressant]] | |||
* [[tricyclic antidepressant]] | |||
==External links== | |||
* [http://www.medicinenet.com/desipramine/article.htm Desipramine] - medicinenet.com | |||
* [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682387.html Desipramine] - medlineplus.org | |||
{{Antidepressants}} | |||
[[Category:Tricyclic antidepressants]] | |||
{{pharma-stub}} | |||
[[de:Desipramin]] | |||
[[ru:Дезипрамин]] | |||
[[sv:Desipramin]] |
Revision as of 11:40, 14 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Desipramine is a Tricyclic antidepressant that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition 1
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition 1
- Developed by: (Organization)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- There is limited information about Off-Label Non–Guideline-Supported Use of Desipramine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition 1
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition 1
- Developed by: (Organization)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- There is limited information about Off-Label Non–Guideline-Supported Use of Desipramine in pediatric patients.
Contraindications
- Condition 1
- Condition 2
- Condition 3
- Condition 4
- Condition 5
Warnings
Conidition 1
(Description)
Adverse Reactions
Clinical Trials Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Drug Interactions
- (Drug 1)
- (Description)
- (Drug 2)
- (Description)
- (Drug 3)
- (Description)
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Desipramine in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Desipramine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Desipramine during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Desipramine in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Desipramine in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Desipramine in geriatric settings.
Gender
There is no FDA guidance on the use of Desipramine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Desipramine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Desipramine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Desipramine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Desipramine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Desipramine in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Desipramine Administration in the drug label.
Monitoring
There is limited information regarding Desipramine Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Desipramine and IV administrations.
Overdosage
There is limited information regarding Desipramine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Desipramine Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Desipramine Mechanism of Action in the drug label.
Structure
There is limited information regarding Desipramine Structure in the drug label.
Pharmacodynamics
There is limited information regarding Desipramine Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Desipramine Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Desipramine Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Desipramine Clinical Studies in the drug label.
How Supplied
There is limited information regarding Desipramine How Supplied in the drug label.
Storage
There is limited information regarding Desipramine Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Desipramine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Desipramine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Desipramine Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Desipramine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Desipramine Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Desipramine Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
|fileName=}}
File:Desipramine.svg | |
Clinical data | |
---|---|
Routes of administration | oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 73-92% |
Metabolism | Hepatic |
Elimination half-life | 21-23 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C18H22N2 |
Molar mass | 266.381 |
Desipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of norepinephrine. It is sold under the brand names Norpramin® and Pertofrane®. It is used to treat depression, but not considered a first line treatment since the introduction of SSRI antidepressants. Desipramine is an active metabolite of imipramine.
Along with other tricyclics, desipramine has found use in treating neuropathic pain. The mechanism of action seems to involve the activation, through norepinephrine reuptake inhibition, of descending pathways in the spinal cord that block pain signals from ascending to the brain. Desipramine is one of the most potent and selective medications in this respect. It may also be used to treat symptoms of Attention Deficit Disorder, as the underproduction of norepinephrine has been increasingly linked to symptoms associated with Attention Deficit Disorder.
Genotoxity
Desipramin has been shown to be genotoxic in fruit flies and associated with an increased risk of breast cancer in women.[1]
See also
External links
- Desipramine - medicinenet.com
- Desipramine - medlineplus.org
- ↑ British Journal of Cancer 2002: volume 86, pages 92-97
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Tricyclic antidepressants